All News
ACR20 - Opening Day Podcast
Another great way to get highlights from the ACR 2020 meeting - listen in to faculty reports and overviews.
Read Article
#HCQ assoc. w/ ↓platelet activity & ↑vascular health in #SLE:
- 132 patients, 108 on HCQ
- Ex-vivo expts show ↓platelet aggregation & downregulation of platelet functional pathways
- HCQ may improve vascular health in SLE
Abs#0870 #ACR20 @RheumNow
https://t.co/ST9n2HGyhM
Mrinalini Dey DrMiniDey ( View Tweet)
Most ignore pharmacists annoying faxes re safety of QT interval with #hydroxycholoroquine likely the right thing to do! @RheumNow #ACR2020 @CRASCRRheum abstr#431. https://t.co/pXBIDOV2MP
Janet Pope Janetbirdope ( View Tweet)
Hydroxychloroquine may reduce rate of progression of systemic sclerosis associated pulmonary hypertension when initiated early (<18 months).
Prospective, observational study.
@RheumNow #ACR2020 Abs#0925 https://t.co/nj0mNAY5Pe
Robert B Chao, MD doctorRBC ( View Tweet)
Study of 372 new #hydroxychloroquine users suggests risk of #HCQ #retinopathy at 10yrs is lower compared to previous prevalence-based estimates, although dose >5mg/kg may increase this risk.
#RheumTwitter Abs#0540 #ACR20 @RheumNow
https://t.co/kOSToCljeq
Mrinalini Dey DrMiniDey ( View Tweet)
Mayo study found incidence of HCQ retinopathy w/ <5 mg/kg/d 5 years = 0%, at 10 years = 2.5%
(historically w/ 6.5 mg/kg/d 5 yr incidence 1%,10 years 2%, 20 years 20%)
Based on this study, which dose of HCQ will you prescribe?
Abstr#540 #ACR20 @rheumnow
k dao KDAO2011 ( View Tweet)
Will we start getting fine-specificity ACPAs to drive treatment of RA? Abst#0743 shows fs-ACPA (anti-fibrinogen B) predict greater response to ABA+MTX vs MTX alone. #ACR20 @RheumNow. Role of RA antibodies will continue to evolve and guide Rx. https://t.co/pY4mm19Jc7
Eric Dein ejdein1 ( View Tweet)
HCQ Not Associated with QTc Length in SLE and RA Patients: Dr. Janet Pope @Janetbirdope #ACR20
https://t.co/zPIaFIiqr5 https://t.co/Wk8YQpIpo7
Links:
Dr. John Cush RheumNow ( View Tweet)
Consistent data that antimalarials did NOT decrease hospitalization for viral infections in the pre #COVID19 era in US claims database in SLE &RA pts #0002 @RheumNow @CRASCRRheum #ACR20 #ACR2020 https://t.co/nZp5dOeHXB
Janet Pope Janetbirdope ( View Tweet)
ACR Best Abstracts - Day 1
The RheumNow faculty reporters have been glued to their monitors all day, viewing video, reading and listening to abstract presentations and I charged them to earmark those presentations were the “Best” they saw today. Below is the list of most often noted #ACRbest abstracts from Day 1.
Read Article
ACPA+ and subclinical synovitis does not automatically mean developing to RA.
Interesting work by Cleo Rogier et al. Something to consider in pts w/arthralgias & when to start csDMARDs @RheumNow #ACR20 Abstr#481 #ACRbest https://t.co/q3vIITmtq2
sheila RHEUMarampa ( View Tweet)
Methotrexate and Nonalcoholic Fatty Liver Disease: Dr Eric Dein (@ejdein1)
Dr. Eric Dein discusses the findings of abstract #0181 at the #ACR20 annual meeting.
https://t.co/TzbRRbw1Kf https://t.co/vK6EahTyQ8
Links:
Dr. John Cush RheumNow ( View Tweet)
How do you treat ACPA+, subclinical synovitis (US/MRI+)? Abst#0481 reviews 3 cohorts for progression to clinical inflam arthritis. 44-68% did not progress to IA in 1 year, is DMARD over treating? #ACR20 #ACRBest @RheumNow
Eric Dein ejdein1 ( View Tweet)
Who can have sustained DMARD-free remission (SDFR)? Abst#0479 says early DAS response after DMARD initiation in ACPA-negative patients #ACR20
@RheumNow. Who do you try for DMARD-free intervals? https://t.co/EOfPt4YQAu
Eric Dein ejdein1 ( View Tweet)
Perform (annual) skin exams in patients in MTX based on discovery of a new adverse effect signal with use of low dose MTX (median dose 15 mg/wk) with a NNH of 167! Screening 160 RA patients on MTX will identify 1 skin Ca. Amazing #ACR20 Year in Review by @JYazdanyMD. @RheumNow https://t.co/hUCzKSYZnB
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#hydroxychloroquine is not a ‘cutie’ drug. E Park et al showed that HCQ does not increase QT interval in RA & SLE patients including if on other meds that may affect QT but known heart disease excluded from study #ACR20 #ACR2020 @RheumNow abstr#432 @CRASCRRheum https://t.co/FGVPknmj5q
Janet Pope Janetbirdope ( View Tweet)
Abst#0181 out of Korea shows MTX use does not increase prevalence of hepatic steatosis. Encouraging data, though retrospective study may underpin provider bias in riskier patients. #ACR20 @RheumNow. https://t.co/HeR5hroYUh
Eric Dein ejdein1 ( View Tweet)
MTX & liver fibrosis:
71% pts w/low FIB-4i of<1.45
No correlation bet FIB-4 values & cumulative MTX dose
Cumulative MTX dose not sig. ⬆ in pts with FIB-4i >1.45 @RheumNow #ACR20 Abstr#0205 https://t.co/RmyAz9M5fw
sheila RHEUMarampa ( View Tweet)
When prescribing hydroxychloroquine for RA, SLE, or other rheumatic diseases, do you routinely order an EKG (either before or during)? #ACR20 @RheumNow
David Liew drdavidliew ( View Tweet)
Dr Choi et al case control study of methotrexate in RA. No increased risk of NAFLD seen. Increased trigs and BMI associated NAFLD @rheumnow #ACR20 Abstr#0181 https://t.co/WLPuf6Ga1D
Richard Conway RichardPAConway ( View Tweet)